Avadel Pharmaceuticals PLC (AVDL) - Total Assets
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) holds total assets worth $199.45 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Avadel Pharmaceuticals PLC - Total Assets Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's total assets have evolved over time, based on quarterly financial data. Also see how much is Avadel Pharmaceuticals PLC worth for the company's overall valuation and market capitalisation.
Avadel Pharmaceuticals PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Avadel Pharmaceuticals PLC's total assets of $199.45 Million consist of 81.7% current assets and 18.3% non-current assets. Review Avadel Pharmaceuticals PLC (AVDL) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.3% |
| Accounts Receivable | $34.10 Million | 20.8% |
| Inventory | $20.30 Million | 12.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $16.84 Million | 10.3% |
Asset Composition Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AVDL stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avadel Pharmaceuticals PLC's current assets represent 81.7% of total assets in 2024, an increase from 59.5% in 1996.
- Cash Position: Cash and equivalents constituted 31.3% of total assets in 2024, down from 51.8% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 20.8% of total assets.
Avadel Pharmaceuticals PLC Competitors by Total Assets
Key competitors of Avadel Pharmaceuticals PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Avadel Pharmaceuticals PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.76 | 2.97 | 17.44 |
| Quick Ratio | 2.37 | 2.60 | 17.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.74 Million | $84.47 Million | $248.34 Million |
Avadel Pharmaceuticals PLC - Advanced Valuation Insights
This section examines the relationship between Avadel Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.62 |
| Latest Market Cap to Assets Ratio | 12.93 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | $164.24 Million |
| Market Capitalization | $2.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Avadel Pharmaceuticals PLC's assets at a significant premium (12.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Avadel Pharmaceuticals PLC's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual total assets of Avadel Pharmaceuticals PLC from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $164.24 Million | -0.28% |
| 2023-12-31 | $164.70 Million | +24.03% |
| 2022-12-31 | $132.78 Million | -46.30% |
| 2021-12-31 | $247.26 Million | -20.66% |
| 2020-12-31 | $311.64 Million | +105.79% |
| 2019-12-31 | $151.44 Million | -20.42% |
| 2018-12-31 | $190.30 Million | -24.52% |
| 2017-12-31 | $252.11 Million | +2.70% |
| 2016-12-31 | $245.48 Million | +14.19% |
| 2015-12-31 | $214.98 Million | +23.40% |
| 2014-12-31 | $174.21 Million | +49.85% |
| 2013-12-31 | $116.25 Million | -0.90% |
| 2012-12-31 | $117.31 Million | +69.03% |
| 2011-12-31 | $69.40 Million | -6.99% |
| 2010-12-31 | $74.61 Million | -20.87% |
| 2009-12-31 | $94.30 Million | +2.65% |
| 2008-12-31 | $91.86 Million | -9.41% |
| 2007-12-31 | $101.40 Million | -11.74% |
| 2006-12-31 | $114.89 Million | -7.61% |
| 2005-12-31 | $124.35 Million | -14.60% |
| 2004-12-31 | $145.61 Million | +14.42% |
| 2003-12-31 | $127.25 Million | +451.45% |
| 2002-12-31 | $23.08 Million | +27.18% |
| 2001-12-31 | $18.14 Million | -10.88% |
| 2000-12-31 | $20.36 Million | +36.46% |
| 1999-12-31 | $14.92 Million | -41.07% |
| 1998-12-31 | $25.32 Million | +17.76% |
| 1997-12-31 | $21.50 Million | -28.09% |
| 1996-12-31 | $29.90 Million | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more